TO BIG PHARMA’S DISMAY –
July 5, 2024 – That’s according to new data from the CDC, which found that in 2022, 4% of U.S. adults needed OUD treatment. While more than half of the adults who needed OUD treatment received care, about 30% of those with an OUD were enrolled in a treatment program that did not include MAT. MAT, which can include buprenorphine, methadone, and naltrexone, is typically considered the gold standard for treating OUD.
“Expanded communication about the effectiveness of medications for OUD is needed,” the authors of the research wrote. “Increased efforts to engage persons with OUD in treatment that includes medications are essential. Clinicians and other treatment providers should offer or arrange evidence-based treatment, including medications, for patients with OUD. Pharmacists and payers can work to make these medications available without delays.”
